Developer docs
API playgroundTry for free, no card

Search company profiles

Antisense Therapeutics

Full company profile

uuid0006pw9

Namestring
Antisense Therapeutics
Legal namestring
Antisense Therapeutics
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company founded in 2000 and headquartered in Melbourne, listed on the Australian Securities Exchange (ASX: ANP). The company specializes in the discovery and development of RNA-based antisense oligonucleotide therapies and siRNA technologies for targeted genetic intervention in diseases with high unmet medical need.

The company's lead therapeutic program targets elevated Lipoprotein(a) — a genetically determined cardiovascular risk factor affecting approximately 20% of the global population that is largely unresponsive to lifestyle modifications or conventional therapies. In early-phase clinical trials, the company's antisense oligonucleotide therapy has demonstrated up to 98% reduction in Lp(a) levels, representing a potentially significant therapeutic advance for atherosclerotic cardiovascular disease prevention. The company also has positioning within the Duchenne Muscular Dystrophy therapeutic market, forecast to reach $6.01 billion by 2030.

The business operates with a lean team of 1-10 employees, led by CEO and Managing Director Mark Diamond, with Phillip Hains serving as CFO and Company Secretary. Revenue generation has not yet commenced as the company remains in clinical development, with operations funded through equity capital raises — including a $5.5 million raise in January 2020 and an earlier $2.1 million round in 2008. The go-to-market model is anticipated to follow traditional pharmaceutical prescription-based distribution channels once products receive regulatory approval, though specific pricing and channel strategies are not publicly disclosed.

Short descriptiontext

Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company developing RNA-based antisense oligonucleotide therapies targeting genetically determined conditions including elevated Lipoprotein(a) and Duchenne Muscular Dystrophy. It serves patients with high unmet medical need and is publicly listed on the ASX.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
antisense oligonucleotide therapeutics, RNA-based drug development, biopharmaceutical drug discovery, cardiovascular disease therapy, Duchenne muscular dystrophy
Industry2 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical antisense oligonucleotide therapeutics
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Antisense Therapeutics is a biopharmaceutical drug discovery and development company developing RNA-based antisense oligonucleotide therapies. Its lead programs target genetically determined elevated Lipoprotein(a), a causal risk factor for atherosclerotic cardiovascular disease affecting approximately 20% of the global population, with early-phase trials demonstrating up to 98% reduction in Lp(a) levels. The company is also pursuing therapies for Duchenne Muscular Dystrophy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Up to 98% reduction in Lipoprotein(a) in early-phase clinical trials
Product and service1 record
1RNA-based Antisense Oligonucleotide Therapies
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Advancing olpasiran, an siRNA therapy for Lp(a) reduction, in late-stage trials. Comparable as a large-cap entrant into the same Lp(a) therapeutic space with RNA-based modality.

TypeEmerging player
Description

Specializes in RNA-targeted therapeutics, notably for Duchenne Muscular Dystrophy, an indication overlapping with Antisense Therapeutics' pipeline. Comparable in oligonucleotide modality and rare disease focus.

TypeBroad incumbent
Description

Developing pelacarsen, a leading Lp(a)-lowering antisense oligonucleotide in Phase 3 trials. A broad incumbent whose cardiovascular franchise overlaps directly with Antisense Therapeutics' lead indication.

TypeBroad incumbent
Description

Leader in RNAi therapeutics with approved products and cardiovascular pipeline. Comparable in RNA-based therapeutic platform and cardiometabolic disease focus.

TypeEmerging player
Description

Clinical-stage RNA therapy company developing oligonucleotide-based treatments for rare diseases. Comparable as a small-cap RNA therapeutics peer with similar platform approach.

TypeDirect peer
Description

Clinical-stage company developing siRNA therapies for cardiovascular indications including SLN360 for elevated Lp(a). Closely comparable in modality, target indication, and development stage.

TypeDirect peer
Description

Pioneer of antisense oligonucleotide technology with multiple approved and clinical-stage assets targeting cardiovascular and rare diseases. Directly comparable in platform technology and cardiometabolic focus.

TypeEmerging player
Description

Clinical-stage oligonucleotide therapeutics company with programs in cardiovascular and rare diseases. Comparable as an emerging player in the same antisense/oligonucleotide modality space.

TypeDirect peer
Description

Develops RNAi-based therapies for cardiovascular and metabolic diseases, with multiple clinical-stage programs. Directly comparable in RNA-based modality and cardiovascular target overlap.

TypeBroad incumbent
Description

Has an active Lp(a) program using siRNA technology. A large-cap incumbent whose cardiovascular pipeline overlaps with the same genetic risk factor Antisense Therapeutics targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Antisense Therapeutics

Biopharmaceutical antisense oligonucleotide therapeuticsantisense.com.au

Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company developing RNA-based antisense oligonucleotide therapies targeting genetically determined conditions including elevated Lipoprotein(a) and Duchenne Muscular Dystrophy. It serves patients with high unmet medical need and is publicly listed on the ASX.

What Antisense Therapeutics does

Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company founded in 2000 and headquartered in Melbourne, listed on the Australian Securities Exchange (ASX: ANP). The company specializes in the discovery and development of RNA-based antisense oligonucleotide therapies and siRNA technologies for targeted genetic intervention in diseases with high unmet medical need.

The company's lead therapeutic program targets elevated Lipoprotein(a) — a genetically determined cardiovascular risk factor affecting approximately 20% of the global population that is largely unresponsive to lifestyle modifications or conventional therapies. In early-phase clinical trials, the company's antisense oligonucleotide therapy has demonstrated up to 98% reduction in Lp(a) levels, representing a potentially significant therapeutic advance for atherosclerotic cardiovascular disease prevention. The company also has positioning within the Duchenne Muscular Dystrophy therapeutic market, forecast to reach $6.01 billion by 2030.

The business operates with a lean team of 1-10 employees, led by CEO and Managing Director Mark Diamond, with Phillip Hains serving as CFO and Company Secretary. Revenue generation has not yet commenced as the company remains in clinical development, with operations funded through equity capital raises — including a $5.5 million raise in January 2020 and an earlier $2.1 million round in 2008. The go-to-market model is anticipated to follow traditional pharmaceutical prescription-based distribution channels once products receive regulatory approval, though specific pricing and channel strategies are not publicly disclosed.

Antisense Therapeutics firmographics

Firmographics
Name
Antisense Therapeutics
Legal name
Antisense Therapeutics
Website
https://antisense.com.au
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company developing RNA-based antisense oligonucleotide therapies targeting genetically determined conditions including elevated Lipoprotein(a) and Duchenne Muscular Dystrophy. It serves patients with high unmet medical need and is publicly listed on the ASX.
Ownership category
akta.pro rank

Antisense Therapeutics industry classification

Industry
Product category
Biopharmaceutical antisense oligonucleotide therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antisense oligonucleotide therapeutics
  • RNA-based drug development
  • Biopharmaceutical drug discovery
  • Cardiovascular disease therapy
  • Duchenne muscular dystrophy

Where Antisense Therapeutics is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Antisense Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Antisense Therapeutics product offering

Product offering

Core offering

Antisense Therapeutics is a biopharmaceutical drug discovery and development company developing RNA-based antisense oligonucleotide therapies. Its lead programs target genetically determined elevated Lipoprotein(a), a causal risk factor for atherosclerotic cardiovascular disease affecting approximately 20% of the global population, with early-phase trials demonstrating up to 98% reduction in Lp(a) levels. The company is also pursuing therapies for Duchenne Muscular Dystrophy.

Differentiator

Problem solved

Functional benefit

Products and services

  • RNA-based Antisense Oligonucleotide Therapies

Quantifiable outcome

  • Up to 98% reduction in Lipoprotein(a) in early-phase clinical trials

Companies that use Antisense Therapeutics

Customer profile

Segments1 record

Ideal customer profiles3 records

Antisense Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Antisense Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Antisense Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Advancing olpasiran, an siRNA therapy for Lp(a) reduction, in late-stage trials. Comparable as a large-cap entrant into the same Lp(a) therapeutic space with RNA-based modality.
  • Novartis: Developing pelacarsen, a leading Lp(a)-lowering antisense oligonucleotide in Phase 3 trials. A broad incumbent whose cardiovascular franchise overlaps directly with Antisense Therapeutics' lead indication.
  • Alnylam Pharmaceuticals: Leader in RNAi therapeutics with approved products and cardiovascular pipeline. Comparable in RNA-based therapeutic platform and cardiometabolic disease focus.
  • Regeneron Pharmaceuticals: Has an active Lp(a) program using siRNA technology. A large-cap incumbent whose cardiovascular pipeline overlaps with the same genetic risk factor Antisense Therapeutics targets.

Emerging players

  • Sarepta Therapeutics: Specializes in RNA-targeted therapeutics, notably for Duchenne Muscular Dystrophy, an indication overlapping with Antisense Therapeutics' pipeline. Comparable in oligonucleotide modality and rare disease focus.
  • ProQR Therapeutics: Clinical-stage RNA therapy company developing oligonucleotide-based treatments for rare diseases. Comparable as a small-cap RNA therapeutics peer with similar platform approach.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with programs in cardiovascular and rare diseases. Comparable as an emerging player in the same antisense/oligonucleotide modality space.

Direct peers

  • Silence Therapeutics: Clinical-stage company developing siRNA therapies for cardiovascular indications including SLN360 for elevated Lp(a). Closely comparable in modality, target indication, and development stage.
  • Ionis Pharmaceuticals: Pioneer of antisense oligonucleotide technology with multiple approved and clinical-stage assets targeting cardiovascular and rare diseases. Directly comparable in platform technology and cardiometabolic focus.
  • Arrowhead Pharmaceuticals: Develops RNAi-based therapies for cardiovascular and metabolic diseases, with multiple clinical-stage programs. Directly comparable in RNA-based modality and cardiovascular target overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Antisense Therapeutics social profiles

Digital presence

Antisense Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Antisense Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Antisense Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Antisense Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antisense Therapeutics

What does Antisense Therapeutics do?

Antisense Therapeutics is a biopharmaceutical drug discovery and development company developing RNA-based antisense oligonucleotide therapies. Its lead programs target genetically determined elevated Lipoprotein(a), a causal risk factor for atherosclerotic cardiovascular disease affecting approximately 20% of the global population, with early-phase trials demonstrating up to 98% reduction in Lp(a) levels. The company is also pursuing therapies for Duchenne Muscular Dystrophy.

Is Antisense Therapeutics a public or private company?

Antisense Therapeutics is a private company. It is classified as public and is currently operating.

When was Antisense Therapeutics founded?

Antisense Therapeutics was founded in 2000. It employs 1 to 10 people.

Where is Antisense Therapeutics based?

Antisense Therapeutics is headquartered in Melbourne, Australia, in the Oceania region.

Who are Antisense Therapeutics's main competitors?

Broad incumbents on record are Amgen, Novartis, Alnylam Pharmaceuticals and Regeneron Pharmaceuticals. Emerging players are Sarepta Therapeutics, ProQR Therapeutics and Wave Life Sciences. Direct peers are Silence Therapeutics, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals.

Does Antisense Therapeutics have an API?

No public API is recorded for Antisense Therapeutics.

What industry is Antisense Therapeutics in?

Antisense Therapeutics's product category is Biopharmaceutical antisense oligonucleotide therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePositive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trialAntisense Therapeutics announced positive Phase II clinical trial results for ATL1102, an immunomodulatory therapy for Duchenne Muscular Dystrophy, with all nine non-ambulatory participants completing 24 weeks of dosing with an excellent safety profile and no serious adverse events. The trial demonstrated statistically significant reductions in CD3+CD49d+ T cells (p=0.030) and clinically meaningful improvements in upper limb function, with 7 of 9 participants showing increases or no change in PUL2.0 scores and significant improvements in grip and pinch strength compared to historical data. The company plans to advance ATL1102 into a potentially pivotal Phase IIb trial following regulatory advice meetings with European authorities, with the final study report expected in Q1 2020.PR NewswirePositive preliminary results from ATL1102 for DMD Phase II trialAntisense Therapeutics reported positive preliminary results from its Phase II clinical trial of ATL1102 for Duchenne Muscular Dystrophy, with 6 patients completing 24 weeks of dosing showing positive drug effects at both immunomodulatory and disease progression levels. No serious adverse events were reported and the Data Safety Monitoring Board recommended trial continuation with no safety concerns. The company plans to advance to a Phase IIb trial and has confirmed Scientific Advice meetings with three European regulatory authorities to discuss the trial design.NewswireFirst Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics announced the first patient dosing in a Phase II trial of ATL1102, an immunomodulatory therapy for Duchenne muscular dystrophy. The six-month trial at Melbourne's Royal Children's Hospital involves nine non-ambulant patients aged 10-18, with primary endpoints on safety and tolerability. ATL1102 is the only CD49d-targeting drug in clinical trials for DMD.PR NewswireATL1103 Phase II trial results published in the European Journal of EndocrinologyAntisense Therapeutics announced that positive Phase II clinical trial data for ATL1103 (atesidorsen) has been published in the European Journal of Endocrinology, a leading peer-reviewed medical journal. The Phase II trial in 26 acromegaly patients met its primary endpoint with a median 27.8% reduction in serum IGF-I levels at the twice-weekly 200mg dose. The publication is expected to support the company's plans for an ATL1103 Early Access Program in Europe and provides independent validation of the drug candidate.GlobeNewswireAntisense Therapeutics to Present at Rodman & Renshaw Annual Global Investment ConferenceAntisense Therapeutics will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on September 13, 2010, with CEO Mark Diamond leading the presentation. The company also announced progress on licensing opportunities for its product pipeline, including ATL1101 for prostate cancer and ATL1102 for multiple sclerosis.GlobeNewswireAntisense Therapeutics Drug ATL1101 Enhances Effect of Existing Chemotherapy Treatment on Prostate TumorsAntisense Therapeutics reported that its drug ATL1101 significantly enhanced Paclitaxel's tumor-suppressive effect in prostate cancer models. In mouse studies, tumor volume was halved after 5 weeks of combination treatment, and cell culture showed reduced Paclitaxel needed for apoptosis. The company is in dialogue about continued development.GlobeNewswireAntisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd.Antisense Therapeutics licensed its MS drug ATL1102 to Teva under an exclusive worldwide deal. Teva pays $2M up-front and can earn up to $100M in milestones, while ANP continues the Phase IIa trial with results due mid-2008.